Functional Analysis of a Canalicular Multispecific Organic Anion Transporter Cloned from Rat Liver*
暂无分享,去创建一个
Y. Sugiyama | Takao Shimizu | K. Kume | H. Suzuki | Kousei Ito | K. Ito | T. Hirohashi | T. Shimizu | H. Suzuki
[1] Y. Sugiyama,et al. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. , 1997, The Journal of pharmacology and experimental therapeutics.
[2] Y. Sugiyama,et al. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). , 1997, The Journal of pharmacology and experimental therapeutics.
[3] S. Cole,et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. , 1996, Biochemical pharmacology.
[4] K. Kohno,et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.
[5] T. Ishikawa,et al. Coordinated Induction of MRP/GS-X Pump and γ-Glutamylcysteine Synthetase by Heavy Metals in Human Leukemia Cells* , 1996, The Journal of Biological Chemistry.
[6] D. Keppler,et al. cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats* , 1996, The Journal of Biological Chemistry.
[7] S. Cole,et al. Biology of the multidrug resistance-associated protein, MRP. , 1996, European journal of cancer.
[8] S. Cole,et al. Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. , 1996, Molecular pharmacology.
[9] D. Keppler,et al. Absence of the canalicular isoform of the MRP gene–encoded conjugate export pump from the hepatocytes in Dubin‐Johnson syndrome , 1996, Hepatology.
[10] M. Müller,et al. Secretion of Organic Anions by Hepatocytes: Involvement of Homologues of the Multidrug Resistance Protein , 1996, Seminars in liver disease.
[11] S. Cole,et al. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. , 1996, The Journal of biological chemistry.
[12] D. Keppler,et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. , 1996, Cancer research.
[13] P. Bosma,et al. Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.
[14] J. Inazawa,et al. Reconstitution of IKATP: An Inward Rectifier Subunit Plus the Sulfonylurea Receptor , 1995, Science.
[15] Y. Sugiyama,et al. Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats. , 1995, The Journal of pharmacology and experimental therapeutics.
[16] D. Meijer,et al. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. , 1995, Biochimica et biophysica acta.
[17] M. Saxena,et al. ATP-dependent Efflux of 2,4-Dinitrophenyl-S-glutathione , 1995, The Journal of Biological Chemistry.
[18] P. Borst,et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[19] Y. Sugiyama,et al. Multiple systems for the biliary excretion of organic anions in rats: liquiritigenin conjugates as model compounds. , 1994, The Journal of pharmacology and experimental therapeutics.
[20] D. Keppler,et al. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. , 1994, Gastroenterology.
[21] Y. Sugiyama,et al. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. , 1993, The Journal of pharmacology and experimental therapeutics.
[22] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[23] Z. Gatmaitan,et al. Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane vesicles. Demonstration of defective ATP-dependent transport in rats (TR-) with inherited conjugated hyperbilirubinemia. , 1992, The Journal of clinical investigation.
[24] J. Alroy,et al. Defective biliary excretion of epinephrine metabolites in mutant (TR−) rats: Relation to the pathogenesis of black liver in the dubin‐johnson syndrome and corriedale sheep with an analogous excretory defect , 1992, Hepatology.
[25] N. Kaplowitz,et al. Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. , 1992, The Journal of biological chemistry.
[26] Yamamura Ken-ichi,et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .
[27] H. Sies,et al. ATP-dependent S-(2,4-dinitrophenyl)glutathione transport in canalicular plasma membrane vesicles from rat liver. , 1991, The Journal of biological chemistry.
[28] T. Ishikawa,et al. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. , 1990, The Journal of biological chemistry.
[29] K. Hayashi,et al. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. , 1990, The Journal of biological chemistry.
[30] W. Lamers,et al. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport , 1985, Hepatology.
[31] F. Johnson,et al. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. , 1954, Medicine.
[32] Y. Sugiyama,et al. Multiple transport systems for organic anions across the bile canalicular membrane. , 1994, The Journal of pharmacology and experimental therapeutics.